Novo Nordisks Ozempic Approval for CKD The FDA has expanded the approval of Ozempic (semaglutide), a GLP-1 receptor agonist, to help reduce kidney disease progression in adults with type 2 diabetes and CKD, marking the first GLP-1 treatment option for this vulnerable patient population
Especially with signs of insulin resistance, prediabetes, sleep apnea or other obesity-related conditions
Losartan administered at different doses caused a dose-dependent decrease in IL-1, IL-6, IL-8, IL-10, IL-17, and TNF- levels
Bidirectional braingutmicrobiota axis in increased intestinal permeability induced by central nervous system injury
Shop now to discover protein powders, creatine powder supplements, multivitamins, and more, designed to support your muscle growth and overall health
Additionally, people using these drugs cut their grocery spending by 6% within six months, as they consume fewer ultra-processed foods